FDA Grants Platform Technology Designation to Precigen's AdenoVerse Immunotherapy Platform
核心洞察
The FDA granted platform technology designation to Precigen's AdenoVerse (搜索) immunotherapeutic platform, which underpins the company's approved product PAPZIMEOS (搜索) for recurrent respiratory papillomatosis (搜索).
The designation allows Precigen to leverage PAPZIMEOS (搜索) manufacturing and preclinical data to support future marketing applications and reduce duplicative development work.
Precigen expects the near-term impact to center on PRGN-2009, which is in Phase 2 testing in HPV-associated oropharyngeal cancer and cervical cancer (搜索).
Precigen announced on Sept. 21, 2026 that the U.S. Food and Drug Administration granted platform technology designation to the AdenoVerse (搜索) immunotherapeutic platform, the technology used in the company's first commercial product, PAPZIMEOS (搜索). The designation covers the platform's use across a broad range of indications, including HPV-positive malignancies such as head and neck, cervical, anal, vulvar and vaginal cancers, as well as other diseases that may be targeted by future AdenoVerse-based candidates.
What the designation changes
According to Precigen, platform technology designation creates a pathway to leverage data generated during the development of PAPZIMEOS (搜索) to potentially accelerate future AdenoVerse (搜索) programs. The company said the designation allows it to use existing manufacturing and preclinical knowledge to support future marketing applications and reduce duplication of development work. It also provides opportunities for early FDA engagement, additional interaction with the agency during development, and consideration of prior FDA manufacturing inspections for future applications.
To qualify, a platform must already be used in an FDA-approved product, and the available evidence must demonstrate that it is well characterized, reproducible and has the potential to be adaptable across multiple products without compromising quality, manufacturing or safety. In granting the designation, the FDA determined that the AdenoVerse (搜索) platform can be applied consistently across multiple products and is reasonably likely to generate meaningful efficiencies in the development or manufacturing process and in the regulatory review process.
PRGN-2009 positioned as near-term beneficiary
"This designation has the potential to accelerate the development of Precigen's broader AdenoVerse (搜索) portfolio by allowing us to build on the technology established through PAPZIMEOS (搜索), which was approved by the FDA in August 2025," said Helen Sabzevari, PhD, President and CEO of Precigen. "We expect the near-term impact will be especially meaningful for PRGN-2009 across multiple HPV-associated cancers, including cervical cancer (搜索) and oropharyngeal squamous cell carcinoma (搜索)."
Sabzevari added that the potential extends beyond PRGN-2009 to future AdenoVerse (搜索) candidates targeting additional cancers and other diseases. "This designation will enable us to leverage prior data and engage with the FDA earlier and more frequently, creating opportunities to reduce duplicative work and bring greater speed, efficiency and predictability to the development of future AdenoVerse therapies," she said.
Clinical portfolio and ongoing studies
Precigen's AdenoVerse (搜索) portfolio includes a Phase 2 study of PRGN-2009 in combination with pembrolizumab in newly diagnosed patients with HPV-associated oropharyngeal squamous cell carcinoma (搜索) (NCT05996523) and a Phase 2 study of PRGN-2009 in combination with pembrolizumab in patients with recurrent or metastatic cervical cancer (搜索) (NCT06157151).
The portfolio also includes PAPZIMEOS (搜索) (zopapogene imadenovec-drba (搜索); formerly PRGN-2012), described by the company as the first FDA-approved therapy for the treatment of adults with recurrent respiratory papillomatosis (搜索). An open-label study evaluating the efficacy of redosing PAPZIMEOS in adults with recurrent respiratory papillomatosis is currently enrolling (NCT06538480).
Precigen is a commercial-stage biopharmaceutical company developing precision medicines across immuno-oncology, autoimmune disorders and infectious diseases.